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of all dressing changes were performed by nurses or aux-
iliary nurses in primary health care or home health care.
Surgical procedures (pinch graft, skin grafting, venous
vascular surgery) had been undertaken in 22% of the
patients. The average weekly cost was €114, though it 
differed depending by ulcer size. For ulcers <10cm2 the
weekly cost was €73, while the cost for larger ulcers was
€179. The total direct annual costs for leg ulcers in
Sweden could be estimated at €180 million (2002 prices)
based on a point prevalence of 0.3%. CONCLUSIONS:
Treatment of leg ulcers seems to have improved compared
with previous reports, resulting in slightly decreased
costs. Nevertheless, the costs are still substantial and the
management of these patients requires large resources.
Further development including a more structured man-
agement, more careful selection of dressing products 
and decreased frequency of dressing changes could be
encouraged. Such changes could imply further improve-
ments in wound healing and quality of life for patients
and decreased costs for the health care system and for
society.
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OBJECTIVES: The aim of the study was to estimate the
costs of treating venous leg ulcers (VLU) in Sweden and
the UK and to compare and discuss possible differences
between the two countries. METHODS: Costs for VLU
treatment were estimated with a health economic model
based on resource use data obtained from prospectively
collected patient data, expert panels in Sweden and the
UK, and scientiﬁc publications. The model simulated
costs for healing of an initial ulcer, costs for prevention
of new ulcers in an ulcer free period, and costs of treat-
ing second ulcers for a period of one year. Simulations
were performed for ulcers of durations <6 months or >=6
months and sizes <10cm2 or >=10cm2. RESULTS: For an
initial ulcer with a duration >=6 months and a size >=10
cm2 the mean total treatment costs were €2295 in Sweden
and €1994 in the UK. Costs of prevention in the ulcer-
free period were €127 in Sweden and €45 in the UK. Total
costs for one year were €2797 in Sweden and €2138 in
the UK. Labour accounted for most of the costs in both
countries, while costs of dressings and other material
were about 14% for the initial ulcer in Sweden and 21%
in the UK. Costs of surgical procedures were low in both
countries. Treatment costs decreased in patients with
shorter ulcer duration and smaller ulcer size. Neverthe-
less, the difference in costs between the countries
remained in all groups. CONCLUSIONS: The most
important factor inﬂuencing treatment costs in the two
countries is the frequency of dressing changes resulting in
higher cost of treatment of VLU in Sweden. Other dif-
ferences of importance are the organisation of treatment
and management of VLU.
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OBJECTIVE: The residual risk of transmitting infectious
blood-borne pathogens via blood transfusion persists
despite recent blood safety advances. The INTERCEPT
Blood System (IBS) for platelets has been developed to
further reduce these pathogen transmission risks during
platelet transfusions. The objective of this study was to
assess the cost-effectiveness of using random-donor
platelets (RDP) and single-donor platelets (SDP)
processed with IBS in Spain. METHODS: A literature-
based decision analysis model was used to assess the cost-
effectiveness of the IBS in four patient populations that
account for most of the platelet usage in Spain: 1) a 10-
year-old male with acute lymphocytic leukemia (ALL); 
2) a 50-year-old male with non-Hodgkin’s lymphoma
(NHL); 3) a 60-year-old male undergoing heart bypass
surgery (CABG); and 4) a 70-year-old female undergoing
a hip arthroplasty. Pathogen exposure included HIV,
HCV, HBV, HTLV-I, bacterial sepsis and emerging
pathogens. The model compared projected quality-
adjusted life-year saved (QALY) and costs for patients
receiving untreated vs. treated platelets. RESULTS: The
incremental cost per QALY gained by using RDP + IBS
vs. RDP ranged from €386,525–€1,178,187. Corre-
sponding ﬁgures for SDP + IBS vs. SDP ranged from
€1,082,170–€2,805,297. Inclusion of an emerging
pathogen beneﬁt signiﬁcantly improved the cost ef-
fectiveness to €65,423–€307,311 for RDP and
€300,793–€1,223,349 for SDP. The model was most sen-
sitive to mortality from bacterial contamination and the
number of additional platelet transfusions required due
to IBS treatment. The model was relatively insensitive to
transmission risks from currently known viruses. CON-
CLUSION: The cost effectiveness of IBS for platelets is
comparable to that of other blood safety interventions
(e.g., NAT, plasma inactivation) that are accepted as valu-
able in Spain. Thus, pathogen inactivation with IBS may
be considered as a desirable strategy to ensure the safety
of platelet transfusions and a valuable insurance against
the threat of new emerging pathogens.
